Published in Oncologist on February 01, 2016
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00323882
Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics. Curr Oncol Rep (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
T cell receptor antagonist peptides induce positive selection. Cell (1994) 18.66
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 9.80
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60
T cell activation. Annu Rev Immunol (2009) 7.40
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 6.94
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol (2003) 5.54
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
T-cell-receptor affinity and thymocyte positive selection. Nature (1996) 4.96
Helping the CD8(+) T-cell response. Nat Rev Immunol (2004) 4.90
Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol (2013) 4.75
Fas and Fas ligand: lpr and gld mutations. Immunol Today (1995) 4.69
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res (2004) 4.65
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res (2005) 4.42
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res (2007) 4.41
Regulation of plasma-cell development. Nat Rev Immunol (2005) 3.98
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res (1991) 3.79
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
Spontaneous regression of cancer: preliminary report. Ann Surg (1956) 3.49
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 3.04
The CTL's kiss of death. Cell (1995) 2.80
Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol (2004) 2.77
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett (2004) 2.77
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med (2012) 2.58
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol (2006) 2.35
Cancer; a biological approach. I. The processes of control. Br Med J (1957) 2.29
B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev (2000) 2.17
Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene (2008) 1.97
The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu Rev Immunol (1994) 1.93
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res (2005) 1.82
How the TCR balances sensitivity and specificity for the recognition of self and pathogens. Nat Immunol (2012) 1.80
The precursors of memory: models and controversies. Nat Rev Immunol (2009) 1.75
Delivering the kiss of death. Nat Immunol (2003) 1.72
Plasma cell development: from B-cell subsets to long-term survival niches. Semin Immunol (2008) 1.68
A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol (1999) 1.66
Spontaneous regression of cancer. Cancer Treat Rev (1996) 1.61
Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest (1993) 1.32
Spontaneous regression of cancer: possible mechanisms. In Vivo (1999) 1.28
Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol (2011) 1.12
The synapse and cytolytic machinery of cytotoxic T cells. Curr Opin Immunol (2010) 1.08
Mini-review CD4 T cells are required for CD8 T cell memory generation. Eur J Immunol (2003) 1.05
Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med (2015) 0.96
A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol (1999) 0.94
IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis. J Immunol (2014) 0.94